Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a potent new immunotherapy drug, in a Peter Mac-led clinical trial. The early-phase NP30179 trial involved 60 patients who were treated with glofitamab, a drug which harnesses the patient’s immune system to fight their cancer....
Tag: <span>Lymphoma</span>
Post
Researchers discover compound that fights leukemia and lymphoma
by University of Texas at El Paso Renato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator on a project that identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy....
Post
FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
by Sarah Gantz, The Philadelphia Inquirer Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug Administration announced an investigation into whether the treatment may cause cancer in rare cases. Chimeric...
Post
Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma
by SWOG Cancer Research Network Credit: Unsplash/CC0 Public Domain A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab...
Post
Moffitt researchers discover pathway critical for lymphoma development
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE TAMPA, Fla. — MYC proteins are important regulators of cancer cell growth, proliferation and metabolism through their ability to increase the expression of proteins involved in these processes. Deregulation of MYC proteins occurs in more than half of all cancers and is associated with poor patient prognosis and...
Post
Nuclear medicine therapy cures human non-Hodgkin’s lymphoma in preclinical model by Society of Nuclear Medicine
by Society of Nuclear Medicine Bioluminescence images of untreated and treated mice with human B cell lymphoma. Optimal results occurred with 8.51 MBq of [177Lu]Lu-ofatumumab (bottom row). Ofa = ofatumumab. Credit: Journal of Nuclear Medicine (2022). DOI: 10.2967/jnumed.122.264816 A new nuclear medicine therapy can cure human non-Hodgkin’s lymphoma in an animal model, according to research published in the April issue...
Post
Severe herpesvirus infection beats adult T-cell leukemia/lymphoma
by Impact Journals LLC Credit: Pixabay/CC0 Public Domain In a recently published editorial in the journal Genes & Cancer, researcher Tatsuro Jo from the Japanese Red Cross Nagasaki Genbaku Hospital’s Department of Hematology discussed aggressive type adult T-cell leukemia/lymphoma (ATLL). ATLL caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated with dismal survival...
Post
What are the symptoms of non-Hodgkin lymphoma in females?
Non-Hodgkin lymphoma is a type of cancer that affects the immune system and may cause varying symptoms depending on where it starts or grows. Females and males may develop similar symptoms. The American Cancer Society (ACS) explains that lymphoma affects the body’s lymphatic system, which moves lymph fluid through the body, helping to fight infections...
Post
CAR-T-cell shows promise in patients with lymphoma of the brain and spinal cord in early trial
by Dana-Farber Cancer Institute An artist’s depiction of a T cell. Credit: NIAID A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of...
Post
Technology developed at UH could advance treatment of lymphoma
UNIVERSITY OF HOUSTON IMAGE: NAVIN VARADARAJAN, UNIVERSITY OF HOUSTON M.D. ANDERSON PROFESSOR OF CHEMICAL AND BIOMOLECULAR ENGINEERING, STUDIED THE DYNAMIC INTERACTIONS BETWEEN T CELLS AND TUMOR CELLS TO DETERMINE WHICH PATIENTS ARE LIKELY TO RESPOND TO CAR T-CELL THERAPY TO TREAT LYMPHOMA. CREDIT: UNIVERSITY OF HOUSTON In the war against cancer, one of the most...